Developing antibodies to protect against hantaviruses
Human monoclonal antibodies for hantaviruses
This study is working on developing vaccines and special antibodies to help protect people from hantaviruses, which can make you very sick, so that you can have both long-term and immediate protection against these viruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10863662 on NIH RePORTER |
What this research studies
This research focuses on creating effective medical countermeasures against hantaviruses, which can cause serious diseases in humans. The approach involves both active immunization through vaccines and passive immunization using long-lasting monoclonal antibodies that can provide immediate protection. Researchers will utilize advanced techniques to discover and engineer these antibodies, ensuring they effectively bind to and inhibit the hantavirus. The goal is to develop treatments that can confer protective immunity, similar to vaccines, but with the added benefit of immediate action.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk of hantavirus exposure, such as those living in endemic areas or working in environments where hantaviruses are present.
Not a fit: Patients who are not at risk of hantavirus infections or those with existing immunity to hantaviruses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that provide immediate protection against hantavirus infections.
How similar studies have performed: Previous research has shown promise in developing monoclonal antibodies for other viral infections, indicating potential success for this novel approach.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Crowe, James E — Vanderbilt University Medical Center
- Study coordinator: Crowe, James E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.